Who is sponsoring NCT05680220?

NCT05680220 is sponsored by Klaus Martiny.

What drugs are being tested in NCT05680220?

Interventions in NCT05680220: Neurostimulation System (NSS): Active Setting, Neurostimulation System (NSS): Sham Setting.

What condition does NCT05680220 study?

NCT05680220 studies Major Depressive Disorder, Treatment Resistant Depression.

Is NCT05680220 still recruiting?

NCT05680220 is currently recruiting now. Last updated 3 March 2026.

Last reviewed 2026-03-03 · How we verify

NCT05680220

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

40 Hz Light Neurostimulation for Patients With Depression (FELIX)

Recruiting now NA Last updated 3 March 2026

What this trial tests

NA trial testing Neurostimulation System (NSS): Active Setting in Major Depressive Disorder in 60 participants. Currently enrolling.

Timeline

5 October 2023

Primary endpoint
30 June 2027

30 July 2027

Quick facts

Lead sponsor	Klaus Martiny
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	60
Start date	5 October 2023
Primary completion	30 June 2027
Estimated completion	30 July 2027
Sites	1 location across Denmark

Drugs / interventions tested

Neurostimulation System (NSS): Active Setting
Neurostimulation System (NSS): Sham Setting

Conditions studied

Major Depressive Disorder — all drugs for Major Depressive Disorder →
Treatment Resistant Depression — all drugs for Treatment Resistant Depression →

Sponsor

Klaus Martiny

Who can join

Adults 18 to 75, any sex, with Major Depressive Disorder or Treatment Resistant Depression. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Recent research in mice models of Alzheimer's disease (AD) has demonstrated that one hour per day of exposure to 40 Hz flickering light therapy can halt the disease's progression, and improve cognition and memory. Moreover, recent data suggest that 40 Hz light stimulation may induce neuroplasticity and reduce neuroinflammation. In this study, the investigators aim to evaluate the antidepressant effects of 40 Hz light stimulation in Major Depressive Disorder (MDD). Patients will be exposed to 40 Hz invisible spectral flickering light (active setting) or continuous non-flickering white light (sham setting) in a home setting for 1 hour each day.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Brain Gamma-Stimulation: Mechanisms and Optimization of Impact.
Lushnikov KV, Serov DA, Astashev ME, Kozlov VA, et al · · 2025 · PMID 41463495 · DOI 10.3390/biology14121722
Rationale and design of a double-blinded, randomized placebo-controlled trial of 40 Hz light neurostimulation therapy for depression (FELIX).
Sakalauskaitė L, Hansen LS, Dubois JM, Ploug Larsen M, et al · · 2024 · PMID 38767238 · DOI 10.1080/07853890.2024.2354852

Verify or expand the search:

Other recruiting trials for Major Depressive Disorder

Currently open trials in the same condition.

NCT07219394 — Peer-Delivered Behavioral Activation in a CCBHC · NA · recruiting
NCT06705478 — Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disor · Phase 2 · recruiting
NCT06749392 — An Individual-specific Synchrony Signature · NA · recruiting
NCT07316803 — Group Intervention for Romantic Relationships in Young Adults With Severe Mental Illness · NA · recruiting
NCT07242105 — Optimizing Brain Excitability in Depression · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05680220 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Klaus Martiny
Last refreshed: 3 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05680220.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing